The Evolving Landscape Of Breast Cancer Treatment: From Conventional Approaches To Emerging Innovations
DOI:
https://doi.org/10.52783/jns.v14.3978Keywords:
Breast cancer, targeted therapy, immunotherapy, drug resistance, precision medicine, HER2 inhibitors, CDK4/6 inhibitorsAbstract
Breast cancer remains one of the most prevalent malignancies worldwide, necessitating continuous advancements in treatment strategies to improve patient outcomes. This review explores the current landscape of breast cancer therapies, ranging from conventional approaches such as surgery, radiation therapy, and chemotherapy to emerging targeted and immunotherapeutic modalities. The primary objective of this review is to provide a comprehensive analysis of modern breast cancer treatments, highlighting their mechanisms of action, clinical efficacy, resistance mechanisms, and future directions. Recent advances in targeted therapy, particularly HER2 inhibitors, tyrosine kinase inhibitors (TKIs), CDK4/6 inhibitors, PI3K/AKT/mTOR pathway inhibitors, and PARP inhibitors, have revolutionized breast cancer management, significantly enhancing survival rates. Immunotherapy, including immune checkpoint inhibitors, has shown promise, particularly for triple-negative breast cancer. Despite these advancements, treatment resistance and adverse effects remain significant challenges, necessitating ongoing research into combination strategies, biomarker-driven therapies, and novel therapeutic targets. To ensure a robust and up-to-date synthesis, a structured search strategy was employed across PubMed, Scopus, and Web of Science databases. The search focused on peer-reviewed articles, clinical trials, and meta-analyses published in the last 10 years using keywords such as breast cancer, targeted therapy, immunotherapy, drug resistance, HER2 inhibitors, and precision medicine. Studies were selected based on relevance, clinical significance, and methodological rigor. Future research will focus on overcoming therapeutic resistance, refining combination regimens, and integrating biomarker-driven precision medicine to optimize patient-specific treatment approaches. A multidisciplinary approach, incorporating genomic profiling, immunotherapy, and next-generation targeted therapies, holds the potential to transform breast cancer care and improve long-term survival and quality of life
Downloads
Metrics
References
Noor F, Noor A, Ishaq AR, Farzeen I, Saleem MH, Ghaffar K, Aslam MF, Aslam S, Chen JT. Recent advances in diagnostic and therapeutic approaches for breast cancer: A comprehensive review. Current Pharmaceutical Design. 2021 Jun 1;27(20):2344-65.
Núñez C, Capelo JL, Igrejas G, Alfonso A, Botana LM, Lodeiro C. An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials. 2016 Aug 1;97:34-50.
Haussmann J, Corradini S, Nestle-Kraemling C, Bölke E, Njanang FJ, Tamaskovics B, Orth K, Ruckhaeberle E, Fehm T, Mohrmann S, Simiantonakis I. Recent advances in radiotherapy of breast cancer. Radiation oncology. 2020 Dec;15:1-0.
Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, Zhang Z, Qiu P, Gu X. Advances in immunotherapy for triple-negative breast cancer. Molecular cancer. 2023 Sep 2;22(1):145.
Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, Vishakha N, Behl T, Jha SK, Tang H. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Molecular cancer. 2023 Jul 6;22(1):105.
Luque-Bolivar A, Pérez-Mora E, Villegas VE, Rondón-Lagos M. Resistance and overcoming resistance in breast cancer. Breast Cancer: Targets and Therapy. 2020 Nov 11:211-29.
Arteaga CL. Progress in breast cancer: overview. Clinical Cancer Research. 2013 Dec 1;19(23):6353-9.
Herdiana Y, Husni P, Nurhasanah S, Shamsuddin S, Wathoni N. Chitosan-based nano systems for natural antioxidants in breast cancer therapy. Polymers. 2023 Jul 5;15(13):2953.
Mo K, Kim A, Choe S, Shin M, Yoon H. Overview of solid lipid nanoparticles in breast cancer therapy. Pharmaceutics. 2023 Jul 31;15(8):2065.
Tang, Y., Qiu, L., Li, Z., & Wang, R. (2025). Extracellular matrix shapes cancer stem cell behavior in breast cancer: A mini review. Frontiers in Immunology, 15, 1503021..
Li JJ, Cheng HY, Lee CH, Ng JK, Tsang JY, Tse GM. Single‐cell multiplex immunocytochemistry in cell block preparations of metastatic breast cancer confirms sensitivity of GATA‐binding protein 3 over gross cystic disease fluid protein 15 and mammaglobin. Cancer Cytopathology. 2025 Jan;133(1):e22910.
Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World journal of clinical oncology. 2014 Aug 10;5(3):412.
Zagami P, Carey LA. Triple negative breast cancer: Pitfalls and progress. NPJ breast cancer. 2022 Aug 20;8(1):95.
Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, De Azambuja E, Viale G, Sotiriou C, Piccart M. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. Journal of clinical oncology. 2014 Sep 1;32(25):2794-803.
Wang L, Zhang S, Wang X. The metabolic mechanisms of breast cancer metastasis. Frontiers in Oncology. 2021 Jan 7;10:602416.
Malikova I, Worth A, Aliyeva D, Khassenova M, Kriajevska MV, Tulchinsky E. Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?. Cell Death & Disease. 2025 Mar 5;16(1):155.
Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023 Jun 23;15(7):1796.
Broeker CD. Comparative Genomics in Breast Cancer: Insights From Murine Models to Human Disease Mechanisms (Doctoral dissertation, Michigan State University).
Haque MA, Poullikkas T, Al-Amin Kaisar FM, Haque S, Khatun MH, Mamun A, Khan A. PHLPP1 depletion promotes tumorigenesis and stemness in triple-negative breast cancer cells through AKT signaling. Medical Oncology. 2025 Feb 20;42(3):80.
Pradhan R, Dey A, Taliyan R, Puri A, Kharavtekar S, Dubey SK. Recent advances in targeted nanocarriers for the management of triple negative breast cancer. Pharmaceutics. 2023 Jan 11;15(1):246.
Kotsifaki A, Alevizopoulos N, Dimopoulou V, Armakolas A. Unveiling the immune microenvironment’s role in breast cancer: A glimpse into promising frontiers. International journal of molecular sciences. 2023 Oct 18;24(20):15332.
Orsini A, Diquigiovanni C, Bonora E. Omics technologies improving breast cancer research and diagnostics. International Journal of Molecular Sciences. 2023 Aug 11;24(16):12690.
Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023 Jun 23;15(7):1796.
Mo K, Kim A, Choe S, Shin M, Yoon H. Overview of solid lipid nanoparticles in breast cancer therapy. Pharmaceutics. 2023 Jul 31;15(8):2065.
Mo K, Kim A, Choe S, Shin M, Yoon H. Overview of solid lipid nanoparticles in breast cancer therapy. Pharmaceutics. 2023 Jul 31;15(8):2065.
Herdiana Y, Husni P, Nurhasanah S, Shamsuddin S, Wathoni N. Chitosan-based nano systems for natural antioxidants in breast cancer therapy. Polymers. 2023 Jul 5;15(13):2953.
Arteaga CL. Progress in breast cancer: overview. Clinical Cancer Research. 2013 Dec 1;19(23):6353-9.
Poppi L. Exploring the effect of RAD51/BRCA2 inhibition to pursue synthetic lethality with PARPi in in-vitro models of pancreatic cancer.
Yuan P, Ma N, Xu B. Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiency. Medicinal research reviews. 2024 Nov;44(6):2774-92.
Morganti S, Marra A, De Angelis C, Toss A, Licata L, Giugliano F, Salimbeni BT, Giachetti PP, Esposito A, Giordano A, Bianchini G. PARP inhibitors for breast cancer treatment: a review. JAMA oncology. 2024 May 1;10(5):658-70.
Duda JM. Elucidation of the High-Grade Serous Ovarian Cancer Acetylome to Identify Novel Therapeutic Vulnerabilities (Doctoral dissertation, University of Minnesota).
Luque-Bolivar A, Pérez-Mora E, Villegas VE, Rondón-Lagos M. Resistance and overcoming resistance in breast cancer. Breast Cancer: Targets and Therapy. 2020 Nov 11:211-29.
Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, Vishakha N, Behl T, Jha SK, Tang H. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Molecular cancer. 2023 Jul 6;22(1):105.
Glaviano A, Foo AS, Lam HY, Yap KC, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Molecular cancer. 2023 Aug 18;22(1):138.
Incorvaia L, Perez A, Marchetti C, Brando C, Gristina V, Cancelliere D, Pivetti A, Contino S, Di Giovanni E, Barraco N, Bono M. Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?. Cancer Treatment Reviews. 2023 Dec 1;121:102650.
Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, Pikarsky E, Kudo M, Finn RS. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nature Reviews Clinical Oncology. 2024 Apr;21(4):294-311.
Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, Pikarsky E, Kudo M, Finn RS. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nature Reviews Clinical Oncology. 2024 Apr;21(4):294-311.
Zhang H, Hussin H, Hoh CC, Cheong SH, Lee WK, Yahaya BH. Big data in breast cancer: towards precision treatment. Digital Health. 2024 Nov;10:20552076241293695.
Trayes KP, Sarah EH. Cokenakes. Breast cancer treatment. American family physician. 2021;104(2):171-8.
Hong R, Xu B. Breast cancer: an up‐to‐date review and future perspectives. Cancer communications. 2022 Oct;42(10):913-36.
Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nature reviews Drug discovery. 2023 Feb;22(2):101-26.
Passaro A, Al Bakir M, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, Mountzios G, Wistuba II, Swanton C, Peters S. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell. 2024 Mar 28;187(7):1617-35.
Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Frontiers in pharmacology. 2021 Mar 15;12:628690.
Zhong H, Zhou Z, Wang H, Wang R, Shen K, Huang R, Wang Z. The biological roles and clinical applications of the PI3K/AKT pathway in targeted therapy resistance in HER2-positive breast cancer: a comprehensive review. International Journal of Molecular Sciences. 2024 Dec 13;25(24):13376.
Castel P, Toska E, Engelman JA, Scaltriti M. The present and future of PI3K inhibitors for cancer therapy. Nature cancer. 2021 Jun;2(6):587-97.
Rocca A, Braga L, Volpe MC, Maiocchi S, Generali D. The predictive and prognostic role of RAS–RAF–MEK–ERK pathway alterations in breast cancer: revision of the literature and comparison with the analysis of cancer genomic datasets. Cancers. 2022 Oct 28;14(21):5306.
Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nature Reviews Drug Discovery. 2023 Mar;22(3):213-34.
Lu B, Natarajan E. Combination Therapy Strategies and Advanced Biomarkers Can Potentially Enhance The Precision-Medicine Treatment of Metastatic Breast Cancer. Journal of Natural Science, Biology and Medicine. 2024 Jul;15(2):266.
Guo L, Shao W, Zhou C, Yang H, Yang L, Cai Q, Wang J, Shi Y, Huang L, Zhang J. Neratinib for HER2-positive breast cancer with an overlooked option. Molecular Medicine. 2023 Oct 6;29(1):134.
Pandey K, Katuwal NB, Park N, Hur J, Cho YB, Kim SK, Lee SA, Kim I, Lee SR, Moon YW. Combination of abemaciclib following eribulin overcomes palbociclib-resistant breast cancer by inhibiting the G2/M cell cycle phase. Cancers. 2022 Jan 1;14(1):210.
Larroquette M, Domblides C, Lefort F, Lasserre M, Quivy A, Sionneau B, Bertolaso P, Gross-Goupil M, Ravaud A, Daste A. Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. European Journal of Cancer. 2021 Nov 1;158:47-62.
Nandi D, Sharma D. Integrating immunotherapy with conventional treatment regime for breast cancer patients-an amalgamation of armamentarium. Frontiers in Immunology. 2024 Nov 1;15:1477980.
Anbarasu S, Anbarasu A. Cancer-biomarkers associated with sex hormone receptors and recent therapeutic advancements: a comprehensive review. Medical Oncology. 2023 May 10;40(6):171.
Idris OA, Deleon N, Gustafson M, Haj D, Zhang T. Precision Medicine Approaches in Breast Cancer: Current Strategies and Future Directions.
Daly RJ, Scott AM, Klein O, Ernst M. Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. Molecular cancer. 2022 Sep 29;21(1):189.
Obeagu EI, Obeagu GU. Predictive models and biomarkers for survival in stage III breast cancer: a review of clinical applications and future directions. Annals of Medicine and Surgery. 2024 Oct 1;86(10):5980-7.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
